News

Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business

MATAWAN, N.J. & EUGENE, Ore.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon's Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the health.

10/14/2025

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego's Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry. Future Labs is part of Apimeds' ai² innovation.

09/15/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Apimeds Pharmaceuticals US, Inc (APUS) a buy, sell, or hold?

Apimeds Pharmaceuticals US, Inc (APUS) can sell. Click on Rating Page for detail.

What is Apimeds Pharmaceuticals US, Inc's stock price?

The price of Apimeds Pharmaceuticals US, Inc (APUS) is 2.3758 and it was updated on 2025-11-07 11:00:26.

Is Apimeds Pharmaceuticals US, Inc (APUS) overvalued or undervalued?

Currently Apimeds Pharmaceuticals US, Inc (APUS) is in undervalued.

News

From:

To:

News
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration's (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company's lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled “Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry”, can be found here: https://www.fda.gov/regulatory-inform. Thu, Sep. 11, 2025
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business's STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders. Future Labs is part of Apimeds' ai² innovation platform, connectin. Mon, Aug. 25, 2025
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Dr. Kramer brings more than 30 year. Tue, Jul. 15, 2025
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.” Mon, May. 12, 2025
U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street research is expected for three companies in the week ahead, and one lock-up period will be expiring. Sat, May. 10, 2025

SEC Filings

SEC Filings
Apimeds Pharmaceuticals US, Inc (APUS) - 4 SEC Filings 10/24/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 4 SEC Filings 10/21/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 4 SEC Filings 10/17/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-K - Current report SEC Filings 10/16/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 10-Q - Quarterly Report SEC Filings 08/19/2025
Apimeds Pharmaceuticals US, Inc (APUS) - NT 10-Q - Quarterly Report SEC Filings 08/14/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-K - Current report SEC Filings 07/16/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 4/A SEC Filings 06/11/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 3/A SEC Filings 06/11/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-K - Current report SEC Filings 06/05/2025
Apimeds Pharmaceuticals US, Inc (APUS) - S-8 SEC Filings 05/23/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-K - Current report SEC Filings 05/20/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 4 SEC Filings 05/20/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 10-Q - Quarterly Report SEC Filings 05/20/2025
Apimeds Pharmaceuticals US, Inc (APUS) - SCHEDULE 13D SEC Filings 05/19/2025
Apimeds Pharmaceuticals US, Inc (APUS) - NT 10-Q - Quarterly Report SEC Filings 05/15/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 4 SEC Filings 05/15/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 4 SEC Filings 05/14/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 3/A SEC Filings 05/14/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-K - Current report SEC Filings 05/12/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 424B4 SEC Filings 05/09/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 3 SEC Filings 05/08/2025
Apimeds Pharmaceuticals US, Inc (APUS) - EFFECT SEC Filings 05/06/2025
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 05/05/2025
Apimeds Pharmaceuticals US, Inc (APUS) - EFFECT SEC Filings 05/05/2025
Apimeds Pharmaceuticals US, Inc (APUS) - CORRESP SEC Filings 05/05/2025
Apimeds Pharmaceuticals US, Inc (APUS) - POS AM SEC Filings 05/02/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 10-K/A - Current report SEC Filings 05/02/2025
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 05/01/2025
Apimeds Pharmaceuticals US, Inc (APUS) - POS AM SEC Filings 05/01/2025
Apimeds Pharmaceuticals US, Inc (APUS) - CORRESP SEC Filings 05/01/2025
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 04/30/2025
Apimeds Pharmaceuticals US, Inc (APUS) - POS AM SEC Filings 04/17/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-K - Current report SEC Filings 04/15/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 10-K - Current report SEC Filings 04/15/2025
Apimeds Pharmaceuticals US, Inc (APUS) - NT 10-K - Current report SEC Filings 03/31/2025
Apimeds Pharmaceuticals US, Inc (APUS) - CERT SEC Filings 03/04/2025
Apimeds Pharmaceuticals US, Inc (APUS) - 8-A12B SEC Filings 03/03/2025
Apimeds Pharmaceuticals US, Inc (APUS) - EFFECT SEC Filings 02/12/2025
Apimeds Pharmaceuticals US, Inc (APUS) - EFFECT SEC Filings 02/11/2025
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 02/10/2025
Apimeds Pharmaceuticals US, Inc (APUS) - FWP SEC Filings 02/10/2025
Apimeds Pharmaceuticals US, Inc (APUS) - CORRESP SEC Filings 02/10/2025
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 02/07/2025
Apimeds Pharmaceuticals US, Inc (APUS) - CORRESP SEC Filings 02/07/2025
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 02/06/2025
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 01/29/2025
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 01/10/2025
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 12/20/2024
Apimeds Pharmaceuticals US, Inc (APUS) - CORRESP SEC Filings 12/19/2024
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 12/16/2024
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 12/09/2024
Apimeds Pharmaceuticals US, Inc (APUS) - S-1/A SEC Filings 11/08/2024
Apimeds Pharmaceuticals US, Inc (APUS) - S-1 SEC Filings 09/25/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRS/A SEC Filings 08/05/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRSLTR SEC Filings 08/02/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRS/A SEC Filings 06/17/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRSLTR SEC Filings 06/14/2024
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 05/23/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRSLTR SEC Filings 05/13/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRS/A SEC Filings 05/13/2024
Apimeds Pharmaceuticals US, Inc (APUS) - UPLOAD SEC Filings 02/26/2024
Apimeds Pharmaceuticals US, Inc (APUS) - DRS SEC Filings 01/29/2024

Press Releases

StockPrice Release
Apimeds pharmaceuticals says “i love my ducks” with new ai² futures lab™ program collaboration with the university of oregon's lundquist college of business 10/14/2025
Apimeds expands ai² future labs program to include university of san diego students in biotech business development 09/15/2025
Apimeds welcomes fda draft guidance as catalyst for advancing apitox non-opioid pain program 09/11/2025
Apimeds pharmaceuticals us, inc. partners with university of alabama to advance biotech business development via ai² future labs 08/25/2025
Apimeds expands leadership team with dr. susan kramer to lead product development and brian peters to lead its ai² division 07/15/2025
Apimeds pharmaceuticals us, inc. announces closing of initial public offering 05/12/2025

Unlock

APUS Ratings Summary

APUS Quant Ranking

Is Apimeds Pharmaceuticals US, Inc (APUS) a buy, sell, or hold?

What is Apimeds Pharmaceuticals US, Inc's stock price?

Is Apimeds Pharmaceuticals US, Inc (APUS) overvalued or undervalued?

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt